Enavate Sciences Gp, LLC

Enavate Sciences Gp, LLC reported 8 holdings worth US$280M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Enavate Sciences Gp, LLC reported 8 holdings worth US$280M as of Sep 30, 2026. Largest: Zenas BioPharma, Inc., Immunome, Inc. and Braveheart Bio, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
8
Value as reported
US$280M

The filing in full

CompanySharesValue as reported% of portfolio
Zenas BioPharma, Inc.2.92MUS$78.7M28.1%
Immunome, Inc.3.61MUS$77.7M27.8%
Braveheart Bio, Inc.3.67MUS$74.2M26.5%
Sionna Therapeutics, Inc.2.48MUS$13M4.7%
Upstream Bio, Inc.2.46MUS$13M4.6%
BridgeBio Oncology Therapeutics, Inc.2.63MUS$10.8M3.8%
Compass Therapeutics, Inc.7.79MUS$8.1M2.9%
CAMP4 Therapeutics Corporation1.04MUS$4.21M1.5%

Source

Download original · View original at SEC

Related